The experience of using PRLT with a Lu-177-labelled small molecule targeting PSMA began in April 2013. This approach using the PSMA ligands to target systemic therapy proved to be successful for treating Metastatic Castration-Resistant Prostate Cancer, especially after the exhaustion of conventional therapies.

Please consult the Journal of Nuclear Medicine 2016 for the details of the comprehensive study from the April 2013 to April 2016 time period.  This paper can be downloaded from this site. See under Presentations / PDFs, subheading under Prostate, Kulkarni & Baum-2016.

Below are some of the conclusions derived from this 3-year study.

• PRLT using the Lu-177 labeled PSMA ligands was highly effective in the treatment of metastatic castration-resistant prostate cancer, even in advanced cases.
• There was significant improvement in clinical symptoms.
• Excellent palliation with low or minimal toxicity.